Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Beats Estimates By $1.20 EPS

Key Points

• Theravance Biopharma reported a quarterly EPS of $1.08, significantly exceeding the consensus estimate of ($0.12).
• Shares of Theravance Biopharma saw a 4.6% increase on the trading day, reaching $11.92.
• Wall Street analysts have mixed views on the stock, with ratings ranging from "downgraded to hold" to a "strong-buy" rating with a $24 target price.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $1.20, Zacks reports. The firm had revenue of $26.20 million during the quarter, compared to analyst estimates of $16.04 million. Theravance Biopharma had a return on equity of 6.93% and a net margin of 16.88%.

Theravance Biopharma Stock Performance

NASDAQ TBPH traded up $0.21 on Friday, reaching $13.15. The company had a trading volume of 730,514 shares, compared to its average volume of 307,451. The firm has a market capitalization of $662.23 million, a price-to-earnings ratio of 54.79 and a beta of 0.01. Theravance Biopharma has a 1-year low of $7.88 and a 1-year high of $13.25. The company's fifty day moving average is $11.19 and its 200-day moving average is $9.99.

Analyst Upgrades and Downgrades

TBPH has been the subject of a number of research reports. BTIG Research increased their price target on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, June 27th. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday. Finally, Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective on the stock in a report on Tuesday, June 17th.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the sale, the senior vice president directly owned 326,918 shares of the company's stock, valued at $3,723,596.02. The trade was a 2.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 44,000 shares of company stock worth $491,800. Insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC acquired a new position in shares of Theravance Biopharma during the 1st quarter worth approximately $101,000. Jane Street Group LLC grew its holdings in shares of Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock valued at $1,258,000 after buying an additional 88,540 shares during the last quarter. Creative Planning purchased a new position in Theravance Biopharma during the second quarter worth about $139,000. American Century Companies Inc. raised its position in Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company's stock worth $1,009,000 after acquiring an additional 5,794 shares during the period. Finally, Invesco Ltd. raised its position in shares of Theravance Biopharma by 12.4% in the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company's stock valued at $279,000 after purchasing an additional 2,789 shares during the period. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.